<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623124</url>
  </required_header>
  <id_info>
    <org_study_id>RJNeuroBank-Dementia</org_study_id>
    <nct_id>NCT05623124</nct_id>
  </id_info>
  <brief_title>Ruijin Neurobank of Alzheimer's Disease and Dementia</brief_title>
  <acronym>RJNB-AD</acronym>
  <official_title>Neurovascular Coupling and Digital Biomarkers in Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this observational study is to learn about neuroimage and biomarkers in the&#xD;
      Alzheimer's continuum. The main questions it aims to answer are:&#xD;
&#xD;
        -  How is the neurovascular coupling during AD pathogenesis?&#xD;
&#xD;
        -  How is the pattern/mapping of alterations in AD biomarkers? Participants will be&#xD;
           observed and visit the research center annually to perform multi-modal MRI, PET,&#xD;
           neuropsychological tests, and blood tests.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The observational study recruits participants from clinics and communities with cognitive&#xD;
      impairment. Healthy volunteers will also be recruited as controls. Longitudinal observation&#xD;
      of these participants will help demonstrate AD biomarkers' significance during AD&#xD;
      pathogenesis.&#xD;
&#xD;
      The investigators aim to build an aging population cohort covering the AD continuum and&#xD;
      explore key biomarkers for AD. All participants will have multi-modal MRI scanning, PET&#xD;
      scanning with different tracers, and blood test. With MRI scanning, the investigators are&#xD;
      exploring the effect of neurovascular coupling in AD pathogenesis. In addition, the&#xD;
      investigators are trying to find patterns/mapping of AD biomarkers with PET and blood tests.&#xD;
      Beyond this, more neuroimage markers and digital biomarkers will be tested in the cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 22, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MMSE</measure>
    <time_frame>once a year</time_frame>
    <description>Mini-mental state examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clock drawing test</measure>
    <time_frame>once a year</time_frame>
    <description>Clock drawing test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complex figure test</measure>
    <time_frame>once a year</time_frame>
    <description>Rey-Osterich complex figure test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AVLT</measure>
    <time_frame>once a year</time_frame>
    <description>Auditory verbal learning test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SDT</measure>
    <time_frame>once a year</time_frame>
    <description>Symbol-digit test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>TMT</measure>
    <time_frame>once a year</time_frame>
    <description>Trail making test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Naming test</measure>
    <time_frame>once a year</time_frame>
    <description>Boston naming test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluency</measure>
    <time_frame>once a year</time_frame>
    <description>Language fluency test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuroimage markers from MRI</measure>
    <time_frame>once a year</time_frame>
    <description>Annual changes of volumes of brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuroimage functional markers from fMRI</measure>
    <time_frame>once a year</time_frame>
    <description>Annual changes of hippocampus related neural connectivity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beta-amyloid</measure>
    <time_frame>once a year</time_frame>
    <description>Annual changes of beta-amyloid in the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tau</measure>
    <time_frame>once a year</time_frame>
    <description>Annual changes of tau in the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SV2A</measure>
    <time_frame>once a year</time_frame>
    <description>Annual changes of synaptic vesicle 2A in the brain</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Dementia</arm_group_label>
    <description>Participants have cognitive impairment and difficulty in daily activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <description>Participants have cognitive impairment, but no difficulty in daily activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cognitively normal</arm_group_label>
    <description>Participants do not have cognitive impairment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Dementia</arm_group_label>
    <arm_group_label>Mild cognitive impairment</arm_group_label>
    <arm_group_label>cognitively normal</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, and DNA extracted from white blood cell&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population consists of Alzheimer's disease, mild cognitive impairment, and cognitively&#xD;
        normal participants.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female aged 50 to 90 years old;&#xD;
&#xD;
          2. In accordance with the diagnostic criteria for &quot;mild cognitive impairment due to&#xD;
             Alzheimer's disease&quot; and &quot;Dementia&quot; from the National Institutes of Health National&#xD;
             Institute on Aging-Alzheimer's Association (NIA-AA) (2011);&#xD;
&#xD;
          3. The Hamilton depression rating scale/17 edition (HAMD) total score&lt;10;&#xD;
&#xD;
          4. The clinical dementia rating (CDR) is 0.5 or above;&#xD;
&#xD;
          5. Neurological examination: no obvious signs;&#xD;
&#xD;
          6. Participants should have a caregiver stable and reliable.&#xD;
&#xD;
          7. Education: primary school (grade 6) or above. They have the ability to complete tests&#xD;
             for cognitive ability and have the ability and time to complete regulation of&#xD;
             cognitive training&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other causes of cognitive decline: cerebrovascular disease, central nervous system&#xD;
             infection, CJD, Huntington's and Parkinson's disease, DLB, traumatic brain dementia,&#xD;
             other physical and chemical factors (such as drugs, alcohol, CO), systemic disease&#xD;
             (hepatic encephalopathy, pulmonary encephalopathy, etc.), intracranial occupation (a&#xD;
             subdural hematoma, brain tumor), the endocrine system disease (thyroid disease,&#xD;
             parathyroid disease), and vitamins deficiency or any other causes of dementia.&#xD;
&#xD;
          2. The history of nervous system diseases, including stroke, optic myelitis, Parkinson's&#xD;
             disease, epilepsy, etc.);&#xD;
&#xD;
          3. Psychiatric patients, including schizophrenia or other mental illnesses, bipolar&#xD;
             disorder, major depression, or delirium;&#xD;
&#xD;
          4. There are unstable or serious heart, lung, liver, kidney, and hematopoietic system&#xD;
             diseases; Poor prognosis because of malignant diseases such as tumors.&#xD;
&#xD;
          5. Vision or hearing problems that lead to poor performance on cognitive tests;&#xD;
&#xD;
          6. Two years history of severe alcoholism, and drug abuse;&#xD;
&#xD;
          7. The researchers believe that the subjects could not complete the study.&#xD;
&#xD;
          8. Contraindication of MRI or PET scanning.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binyin Li, Dr</last_name>
      <phone>86-13681884221</phone>
      <email>libinyin@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiaomeng Xu, Dr</last_name>
      <phone>86-021-64454473</phone>
      <email>xuxiaomeng@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 23, 2022</study_first_submitted>
  <study_first_submitted_qc>November 14, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>November 14, 2022</last_update_submitted>
  <last_update_submitted_qc>November 14, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is not yet a plan to make IPD available to other researchers</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

